[0012a] In one aspect of the present disclosure, there is provided a compound having formula (I):



(I)

or a pharmaceutically acceptable salt, hydrate, solvate, or rotamer thereof,

wherein

A is a carboxylic acid moiety or a carboxylic acid isostere;

ring vertices a, b, c and d are independently selected from CH and $C(R^1)$;

each R^1 is independently selected from the group consisting of halogen, CN, $-SF_5$, C_{1-8} alkyl, C_{3-8} cycloalkyl, C_{2-8} alkenyl, C_{2-8} alkynyl, C_{1-8} haloalkyl, $-OR^a$, $-SR^a$, $-COR^a$, $-NR^aR^b$, and 5- or 6-membered heteroaryl, wherein the alkyl portions of R^1 are optionally further substituted with 1-3 R^a; and optionally, adjacent R^1 members are connected to form an additional 5- or 6-membered ring which is saturated or unsaturated having ring vertices selected from C, O, S and N, wherein the additional 5- or 6-membered ring is optionally substituted with one or two members selected from the group consisting of halogen, hydroxyl, C_{1-4} alkyl, C_{1-4} alkoxy and C_{1-4} haloalkyl;

the subscript n is an integer of from 0 to 3;

each R^3 is independently selected from the group consisting of halogen, CN, C_{1-8} alkyl, C_{3-8} cycloalkyl, C_{2-8} alkenyl, C_{2-8} alkynyl, C_{1-8} haloalkyl, aryl, $-OR^a$, $-NR^aR^b$ and $-N(R^a)$-C_1-C_4 alkylene-OR^b, and wherein the alkyl or aryl portions of R^2 and R^3 are optionally further substituted with 1-3 R^a;

Ar is a benzene or pyridine ring that is optionally substituted with from 1 to 5 R^4 substituents independently selected from the group consisting of halogen, CN, $-SF_5$, C_{1-8} alkyl, C_{3-8} cycloalkyl, C_{2-8} alkenyl, C_{2-8} alkynyl, C_{1-8} haloalkyl, C_{1-8} hydroxyalkyl, $-OR^a$, $-NR^aR^b$,

and wherein the alkyl and cycloalkyl, portions of R^4 are optionally further substituted with 1-3 R^a;

each R^a and R^b is independently selected from the group consisting of hydrogen, hydroxyl, halogen, cyano, C_{1-4} alkyl, C_{1-4} alkoxy, C_{1-4} haloalkyl, C_{3-6} cycloalkyl, amino, C_{1-8} alkylamino, and di C_{1-8} alkylamino, or when attached to a nitrogen atom are optionally combined to form a 4- to 7-membered saturated ring, which is optionally substituted with oxo.

[0012b] In another aspect of the present disclosure, there is provided a pharmaceutical composition comprising a compound disclosed herein, or a pharmaceutically acceptable salt, hydrate, solvate, or rotamer thereof, with a pharmaceutically acceptable excipient.

[0012c] In a further aspect of the present disclosure, there is provided a use of a compound disclosed herein, or a pharmaceutically acceptable salt, hydrate, solvate, or rotamer thereof, in the manufacture of a medicament for treating a disease or condition modulated at least in part by CCR6, wherein said disease or condition is an inflammatory disease or condition.

[0012d] In another aspect of the present disclosure, there is provided a compound disclosed herein, or a pharmaceutically acceptable salt, hydrate, solvate, or rotamer thereof, for use in treating a disease or condition modulated at least in part by CCR6.

WHAT IS CLAIMED IS:

1. A compound having formula (I):



(I)

or a pharmaceutically acceptable salt, hydrate, solvate, or rotamer thereof, wherein

A is a carboxylic acid moiety or a carboxylic acid isostere;

ring vertices a, b, c and d are independently selected from CH and C(R^1);

each R^1 is independently selected from the group consisting of halogen, CN, -SF_5, C_{1-8} alkyl, C_{3-8} cycloalkyl, C_{2-8} alkenyl, C_{2-8} alkynyl, C_{1-8} haloalkyl, -OR^a, -SR^a, -COR^a, -NR^aR^b, and 5- or 6-membered heteroaryl, wherein the alkyl portions of R^1 are optionally further substituted with 1-3 R^a; and optionally, adjacent R^1 members are connected to form an additional 5- or 6-membered ring which is saturated or unsaturated having ring vertices selected from C, O, S and N, wherein the additional 5- or 6-membered ring is optionally substituted with one or two members selected from the group consisting of halogen, hydroxyl, C_{1-4} alkyl, C_{1-4} alkoxy and C_{1-4} haloalkyl;

the subscript n is an integer of from 0 to 3;

each R^3 is independently selected from the group consisting of halogen, CN, C_{1-8} alkyl, C_{3-8} cycloalkyl, C_{2-8} alkenyl, C_{2-8} alkynyl, C_{1-8} haloalkyl, aryl, -OR^a, -NR^aR^b and -N(R^a)-C_1-C_4 alkylene-OR^b, and wherein the alkyl or aryl portions of R^2 and R^3 are optionally further substituted with 1-3 R^a;

Ar is a benzene or pyridine ring that is optionally substituted with from 1 to 5 R^4 substituents independently selected from the group consisting of halogen, CN, -SF_5, C_{1-8} alkyl, C_{3-8} cycloalkyl, C_{2-8} alkenyl, C_{2-8} alkynyl, C_{1-8} haloalkyl, C_{1-8} hydroxyalkyl, -OR^a, -NR^aR^b,

and wherein the alkyl and cycloalkyl, portions of R^4 are optionally further substituted with 1-3 R^a;

each R^a and R^b is independently selected from the group consisting of hydrogen, hydroxyl, halogen, cyano, C_{1-4} alkyl, C_{1-4} alkoxy, C_{1-4} haloalkyl, C_{3-6} cycloalkyl, amino, C_{1-8} alkylamino, and di C_{1-8} alkylamino, or when attached to a nitrogen atom are optionally combined to form a 4- to 7-membered saturated ring, which is optionally substituted with oxo.

2. A compound of claim **1**, wherein ring vertex d is CH.

3. A compound of claim **1**, wherein ring vertices c and d are each CH.

4. A compound of claim **1**, wherein ring vertices a, b, and c are each $C(R^1)$.

5. A compound of claim **1**, wherein ring vertices a and b are each $C(R^1)$.

6. A compound of claim **1**, wherein A is a member selected from the group consisting of $-CO_2H$, $-SO_3H$, $-PO_3H_2$ and a tetrazole.

7. A compound of claim **1**, wherein A is $-CO_2H$,

8. A compound of claim **1**, wherein n is 0 or 1.

9. A compound of claim **1**, wherein n is 0.

10. A compound of claim **1**, wherein Ar is a benzene ring which is optionally substituted with from 1-3 R^4 substituents; A is $-CO_2H$; and d is CH.

11. A compound of claim **10**, wherein the subscript n is 1.

12. A compound of claim **10**, wherein the subscript n is 0.

13. A compound of claim **1**, wherein the ring having a, b, c and d as ring vertices is selected from the group consisting of:





and



wherein the wavy line labeled y indicates the point of attachment to the $NHS(O)_2$ portion of the compound and the wavy line labeled z indicates the point of attachment to the quinoline ring.

14. A compound of claim **10**, wherein Ar is selected from the group consisting of:



wherein the wavy line labeled w indicates the point of attachment to the $S(O)_2$ moiety.

15. A compound of claim **13**, wherein Ar is selected from the group consisting of:

16. A compound of claim **1**, selected from the group consisting of:



















and



.

17. A compound of claim **1**, selected from the group consisting of:





and



or a pharmaceutically acceptable salt, hydrate, solvate, or rotamer thereof.

18. A compound of claim **1**, having the structure



or a pharmaceutically acceptable salt thereof.

19. A compound of claim **1**, having the structure



or a pharmaceutically acceptable salt thereof.

20. A pharmaceutical composition comprising a compound of any of claims **1** to **19**, or a pharmaceutically acceptable salt, hydrate, solvate, or rotamer thereof, with a pharmaceutically acceptable excipient.

21. Use of a compound of any of claims **1** to **19**, or a pharmaceutically acceptable salt, hydrate, solvate, or rotamer thereof, in the manufacture of a medicament for treating a disease or condition modulated at least in part by CCR6, wherein said disease or condition is an inflammatory disease or condition.

22. The use in accordance with claim **21**, wherein said disease or condition is selected from the group consisting of psoriasis, eczema, atopic dermatitis, allergic contact dermatitis, urticaria, puritis, allergic asthma, Crohn's disease, ulcerative colitis, iletis, enteritis, insect string, scleroderma, vaginitis, vasculitis, Grave's disease, Alzheimer's disease, type I diabetes, graft rejection, atherosclerosis, sepsis, sarcoidosis, chronic obstructive pulmonary disease, and sinusitis.

23. The use in accordance with claim **21**, wherein said disease or condition is atopic dermatitis.

24. The use in accordance with claim **21**, wherein said disease or condition is psoriasis.

25. The use in accordance with any of claims **21**, **22**, **23**, or **24**, wherein said compound is a compound of claim **13**, **15**, **16** or **17**, or a pharmaceutically acceptable salt, hydrate, solvate, or rotamer thereof.

26. The use in accordance with claim **25**, wherein the compound is a compound of claim **15**, or a pharmaceutically acceptable salt, hydrate, solvate, or rotamer thereof.

27. The use in accordance with claim **25**, wherein the compound is a compound of claim **16**, or a pharmaceutically acceptable salt, hydrate, solvate, or rotamer thereof.

28. A compound of any of claims **1** to **17**, or a pharmaceutically acceptable salt, hydrate, solvate, or rotamer thereof, for use in treating a disease or condition modulated at least in part by CCR6.